Stocktoria
PHIBRO ANIMAL HEALTH CORP PAHC
PHIBRO ANIMAL HEALTH CORP (PAHC) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.51% (safety: moderate). FY2025 revenue was $1.3B at a 3.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.34 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.38 |
| Retained earnings / assets | 0.2 |
| EBIT / assets | 0.081 |
| Equity / liabilities | 0.266 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PAHC | PHIBRO ANIMAL HEALTH CORP | 5/9 | 3.97 | 26.6 | +27.4% |
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
| ALKS | Alkermes plc. | 5/9 | 6.24 | 38 | -5.2% |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
| ACAD | ACADIA PHARMACEUTICALS INC | 4/9 | 3.79 | 11.1 | +11.9% |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
About PHIBRO ANIMAL HEALTH CORP
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
FAQ
Is PAHC financially healthy?
PHIBRO ANIMAL HEALTH CORP's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PAHC pay a dividend, and is it safe?
Yes. PHIBRO ANIMAL HEALTH CORP pays a dividend yielding about 1.51% with a 40.3% payout ratio, rated “moderate” for safety.
How profitable is PAHC?
In FY2025, PHIBRO ANIMAL HEALTH CORP had a net margin of 3.7% and a return on equity of 16.9%.
Is PAHC overvalued or undervalued?
PHIBRO ANIMAL HEALTH CORP trades at about 28.4× trailing earnings — above its 10-year norm (10-year range 10.0×–314.7×, median 23.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for PAHC?
The average Wall-Street price target for PHIBRO ANIMAL HEALTH CORP is $45.60, about 34.9% above the recent price, from 5 analysts.
Is PAHC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PHIBRO ANIMAL HEALTH CORP: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 26.6×, a dividend yield of 1.51%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.